GameChangers: The FRAIL AF Study
![](https://www.ceimpact.com/wp-content/uploads/product_images/10323_20230929-768x768.jpg)
GameChangers: The FRAIL AF Study
Multiple studies highlight the benefits of direct oral anticoagulants (DOACS) with lower incidence of side effects and non-inferiority to warfarin. Join host, Geoff Wall, and guest, Mathew Boyd, as they discuss the FRAILE AF study and whether warfarin may be the best best in older adults.
THE GAMECHANGER: DOACs are recommended by nearly all relevant major medical guidelines as the anticoagulant of choice in atrial fibrillation. A new study has found that in frail elderly patients, warfarin may be associated with fewer bleeding episodes.
Upon successful completion of this course, learners should be able to:
1. Describe the design and results of the FRAIL AF study
2. Apply the results of the Groningen Frailty Index to a specific patient
Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences
Mathew Boyd, PharmD
Clinical Pharmacist
Unity Point
Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.
Dr. Boyd has no relevant financial relationships with ineligible companies to disclose.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: September 25, 2023
Planned Expiration Date: September 25, 2024
Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
Duration | 0h 30m |
---|---|
Topic Designator | Disease State/Drug Therapy |
ACPE | Yes |
ACPE Topic | 01 Drug Therapy |
Role | Pharmacist |
Media-Type | Podcast |
Release Date | 9/25/23 |
CEUs | 0.05 |
Rating | 4 |
ACPE Number | 0107-0000-23-302-H01-P |
This course is in our subscription.
Related products
-
-
Annual Pharmacy Law Update: How COVID Exposed Legal Dilemmas in Patient Care
Rated 0 out of 5$34.00 -
Avelumab for Urothelial Carcinoma – Improving Overall Survival?
In Courses, PharmacistRated 0 out of 5$24.00